 | |
- close
- close
| |||||||||
Industry (USD) Annual | ||||||||
|---|---|---|---|---|---|---|---|---|
| FISCAL YEAR ENDING |
 |
31-DEC 2004 |
31-DEC 2005 |
31-DEC 2006 |
31-DEC 2007 |
31-DEC 2008 |
 |
|
| Operating Income | |
0 | 0 | 0 | 0 | 3.99B | |
|
| Gross Profit | |
14.3B | 14.2B | 12.9B | 14.0B | 15.0B | |
|
| Total Revenues | |
19.4B | 19.2B | 17.9B | 19.3B | 20.6B | |
|
| Net Income | |
2.39B | 3.00B | 1.58B | 2.17B | 5.25B | |
|
| Gross Margin | |
69.1% | 69.1% | 66.8% | 67.9% | 69% |   | |
| Research and Development Expense | |
2.50B | 2.75B | 3.07B | 3.28B | 3.58B | | |
| R&D/Sales Ratio | |
12.9% | 14.3% | 17.1% | 17% | 17.4% | | |
| Number of Drugs in Phase III | |
0 | 5.00 | 6.00 | 5.00 | 8.00 | | |
| Number of Drug Approvals | |
0 | 2.00 | 0 | 0 | 0 | | |
| ||||||
|
|
